Upregulation of Steroidogenic Acute Regulatory Protein by Hypoxia Stimulates Aldosterone Synthesis in Pulmonary Artery Endothelial Cells to Promote Pulmonary Vascular Fibrosis
Overview
Authors
Affiliations
Background: The molecular mechanism(s) regulating hypoxia-induced vascular fibrosis are unresolved. Hyperaldosteronism correlates positively with vascular remodeling in pulmonary arterial hypertension, suggesting that aldosterone may contribute to the pulmonary vasculopathy of hypoxia. The hypoxia-sensitive transcription factors c-Fos/c-Jun regulate steroidogenic acute regulatory protein (StAR), which facilitates the rate-limiting step of aldosterone steroidogenesis. We hypothesized that c-Fos/c-Jun upregulation by hypoxia activates StAR-dependent aldosterone synthesis in human pulmonary artery endothelial cells (HPAECs) to promote vascular fibrosis in pulmonary arterial hypertension.
Methods And Results: Patients with pulmonary arterial hypertension, rats with Sugen/hypoxia-pulmonary arterial hypertension, and mice exposed to chronic hypoxia expressed increased StAR in remodeled pulmonary arterioles, providing a basis for investigating hypoxia-StAR signaling in HPAECs. Hypoxia (2.0% FiO2) increased aldosterone levels selectively in HPAECs, which was confirmed by liquid chromatography-mass spectrometry. Increased aldosterone by hypoxia resulted from enhanced c-Fos/c-Jun binding to the proximal activator protein-1 site of the StAR promoter in HPAECs, which increased StAR expression and activity. In HPAECs transfected with StAR-small interfering RNA or treated with the activator protein-1 inhibitor SR-11302 [3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid], hypoxia failed to increase aldosterone, confirming that aldosterone biosynthesis required StAR activation by c-Fos/c-Jun. The functional consequences of aldosterone were confirmed by pharmacological inhibition of the mineralocorticoid receptor with spironolactone or eplerenone, which attenuated hypoxia-induced upregulation of the fibrogenic protein connective tissue growth factor and collagen III in vitro and decreased pulmonary vascular fibrosis to improve pulmonary hypertension in vivo.
Conclusion: Our findings identify autonomous aldosterone synthesis in HPAECs attributable to hypoxia-mediated upregulation of StAR as a novel molecular mechanism that promotes pulmonary vascular remodeling and fibrosis.
Cui C, Chen S, Mi B, Qi Y, Jiao C, Zhang M Int J Mol Sci. 2024; 25(22).
PMID: 39596139 PMC: 11593661. DOI: 10.3390/ijms252212071.
Efficacy of spironolactone in pulmonary arterial hypertension.
Kubota K Hypertens Res. 2024; 48(3):1184-1186.
PMID: 39511329 DOI: 10.1038/s41440-024-01976-1.
Zhao P, Li S, He Z, Ma X Animals (Basel). 2024; 14(20).
PMID: 39457960 PMC: 11505238. DOI: 10.3390/ani14203031.
Imano H, Hayashi T, Nomura A, Tanaka S, Kohda Y, Yamaguchi T Hypertens Res. 2024; 47(12):3423-3433.
PMID: 39367269 DOI: 10.1038/s41440-024-01908-z.
An emerging view on vascular fibrosis molecular mediators and relevant disorders: from bench to bed.
Hua R, Gao H, He C, Xin S, Wang B, Zhang S Front Cardiovasc Med. 2024; 10:1273502.
PMID: 38179503 PMC: 10764515. DOI: 10.3389/fcvm.2023.1273502.